×
S&P 500   3,865.23 (+0.88%)
DOW   31,180.40 (+0.69%)
QQQ   290.13 (+1.10%)
AAPL   143.59 (+1.43%)
MSFT   267.26 (+1.68%)
META   171.01 (+1.68%)
GOOGL   2,301.58 (+1.60%)
AMZN   115.07 (+1.38%)
TSLA   697.24 (-0.28%)
NVDA   152.52 (+1.92%)
NIO   20.72 (-6.58%)
BABA   119.44 (-0.57%)
AMD   75.82 (+0.82%)
MU   57.90 (+2.06%)
CGC   2.68 (-1.11%)
T   21.14 (-0.14%)
GE   61.82 (-0.34%)
F   11.15 (-0.45%)
DIS   96.52 (-0.68%)
AMC   12.46 (-2.50%)
PFE   52.69 (+2.03%)
PYPL   73.74 (-0.89%)
NFLX   185.34 (-0.29%)
S&P 500   3,865.23 (+0.88%)
DOW   31,180.40 (+0.69%)
QQQ   290.13 (+1.10%)
AAPL   143.59 (+1.43%)
MSFT   267.26 (+1.68%)
META   171.01 (+1.68%)
GOOGL   2,301.58 (+1.60%)
AMZN   115.07 (+1.38%)
TSLA   697.24 (-0.28%)
NVDA   152.52 (+1.92%)
NIO   20.72 (-6.58%)
BABA   119.44 (-0.57%)
AMD   75.82 (+0.82%)
MU   57.90 (+2.06%)
CGC   2.68 (-1.11%)
T   21.14 (-0.14%)
GE   61.82 (-0.34%)
F   11.15 (-0.45%)
DIS   96.52 (-0.68%)
AMC   12.46 (-2.50%)
PFE   52.69 (+2.03%)
PYPL   73.74 (-0.89%)
NFLX   185.34 (-0.29%)
S&P 500   3,865.23 (+0.88%)
DOW   31,180.40 (+0.69%)
QQQ   290.13 (+1.10%)
AAPL   143.59 (+1.43%)
MSFT   267.26 (+1.68%)
META   171.01 (+1.68%)
GOOGL   2,301.58 (+1.60%)
AMZN   115.07 (+1.38%)
TSLA   697.24 (-0.28%)
NVDA   152.52 (+1.92%)
NIO   20.72 (-6.58%)
BABA   119.44 (-0.57%)
AMD   75.82 (+0.82%)
MU   57.90 (+2.06%)
CGC   2.68 (-1.11%)
T   21.14 (-0.14%)
GE   61.82 (-0.34%)
F   11.15 (-0.45%)
DIS   96.52 (-0.68%)
AMC   12.46 (-2.50%)
PFE   52.69 (+2.03%)
PYPL   73.74 (-0.89%)
NFLX   185.34 (-0.29%)
S&P 500   3,865.23 (+0.88%)
DOW   31,180.40 (+0.69%)
QQQ   290.13 (+1.10%)
AAPL   143.59 (+1.43%)
MSFT   267.26 (+1.68%)
META   171.01 (+1.68%)
GOOGL   2,301.58 (+1.60%)
AMZN   115.07 (+1.38%)
TSLA   697.24 (-0.28%)
NVDA   152.52 (+1.92%)
NIO   20.72 (-6.58%)
BABA   119.44 (-0.57%)
AMD   75.82 (+0.82%)
MU   57.90 (+2.06%)
CGC   2.68 (-1.11%)
T   21.14 (-0.14%)
GE   61.82 (-0.34%)
F   11.15 (-0.45%)
DIS   96.52 (-0.68%)
AMC   12.46 (-2.50%)
PFE   52.69 (+2.03%)
PYPL   73.74 (-0.89%)
NFLX   185.34 (-0.29%)

Unicycive Therapeutics Price Target, Predictions & Analyst Ratings

$0.77
-0.05 (-6.08%)
(As of 07/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.76
$0.81
50-Day Range
$0.70
$1.06
52-Week Range
$0.62
$8.73
Volume
20,448 shs
Average Volume
24,316 shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Unicycive Therapeutics (NASDAQ:UNCY) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$8.50
1,001.04% Upside
High Prediction$13.50
Average Prediction$8.50
Low Prediction$3.00
TypeCurrent
7/6/21 to 7/6/22
1 Month Ago
6/6/21 to 6/6/22
3 Months Ago
4/7/21 to 4/7/22
1 Year Ago
7/6/20 to 7/6/21
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
4 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$8.50$8.25$8.25N/A
Predicted Upside1,001.04% Upside343.55% Upside343.55% UpsideN/A
Get Unicycive Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.


UNCY Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

UNCY Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Unicycive Therapeutics Stock vs. The Competition

TypeUnicycive TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyBuyBuy
Predicted Upside1,001.04% Upside457.94% Upside32.91% Upside
News Sentiment RatingVery Positive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
4
40.00%
Underperform Votes
6
60.00%
Avg. Outperform Votes
167
66.80%
Avg. Underperform Votes
83
33.20%
Avg. Outperform Votes
840
69.08%
Avg. Underperform Votes
376
30.92%

Historical Unicycive Therapeutics Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/8/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00+757.14%
3/16/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$3.00+180.37%
8/17/2021Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
8/9/2021Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Piros
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$13.50+409.43%
(Data available from 7/6/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Unicycive Therapeutics Price Target - Frequently Asked Questions

What is Unicycive Therapeutics's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Unicycive Therapeutics stock is Buy based on the current 4 buy ratings for UNCY. The average twelve-month price prediction for Unicycive Therapeutics is $8.50 with a high price target of $13.50 and a low price target of $3.00. Learn more on UNCY's analyst rating history.

Do Wall Street analysts like Unicycive Therapeutics more than its competitors?

Analysts like Unicycive Therapeutics stock more than the stock of other Medical companies. The consensus rating score for Unicycive Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.72. Learn more on how UNCY compares to other companies.

Do MarketBeat users like Unicycive Therapeutics more than its competitors?

MarketBeat users like Unicycive Therapeutics stock less than the stock of other Medical companies. 40.00% of MarketBeat users gave Unicycive Therapeutics an outperform vote while medical companies recieve an average of 67.07% outperform votes by MarketBeat users.

Does Unicycive Therapeutics's stock price have much upside?

According to analysts, Unicycive Therapeutics's stock has a predicted upside of 434.59% based on their 12-month price targets.

What analysts cover Unicycive Therapeutics?

Unicycive Therapeutics has been rated by HC Wainwright in the past 90 days.

This page (NASDAQ:UNCY) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.